Introduction {#Sec1}
============

Personalized medicine did not begin in the post-genome era. One colleague, trained before Watson and Crick's landmark discovery, asked if she had been practicing "impersonal medicine" all those years. As one historian has put it: "The new language of genomics, as applied to medicine, is less a revolution than an evolution" (Steele [@CR89]). The current enthusiasm, and occasional "hype," about personalized genomics follows several decades of scientific discovery and clinical translation in human genetics. Rather then constituting a new paradigm, personalized genomics is best viewed as incremental to the model built over several decades of the practice of genetic medicine. In this *Perspectives*, we will focus on the lessons learned from genetic medicine, which provide a solid foundation to define the scientific and clinical challenges inherent in the application of genomics to personalized medicine.

The relationship of genomics and personalized medicine {#Sec2}
======================================================

There has long been interest in personalizing medicine. Hippocrates individualized diagnosis and treatment, for example, by giving cold food to a "phlegmatic" person (Steele [@CR89]). Today, personalized medicine, informed by a molecular understanding of disease, has brought new classification systems as well as more effective preventive and therapeutic interventions. Personalized medicine is "a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, and treat disease" (National Cancer Institute [@CR59]). Thus, a physician---even a pre-genomics trained general practitioner---can deliver personalized care in the absence of DNA profiles. This distinction is often garbled. For example, in the version of H.R. 5440 (re-introduced in the last Congress and originally introduced by then-Senator Obama) personalized medicine is defined as "any clinical practice model that emphasizes the systematic use of preventive, diagnostic, and therapeutic interventions that use genome and family history information to improve health outcome" (H.R. 5440, [@CR1]). Such a definition of personalized medicine, while politically correct, incorrectly omits vital non-genetic components including environmental or occupational exposures.

Another semantic distinction, with enormous regulatory, ethical, and practical implications, grows from our assumption that personalized *genomics* must meet the same standards as other components of personalized *medicine*. Some commercial entities sought to define a non-medical role of personal genomics as a "recreational" or "information-seeking" pursuit. In December 2008, a multidisciplinary work shop was convened by the National Institutes of Health and the Centers for Disease Control to review the scientific foundation for using personalized genomics as a component in personalized medicine. The attendees included investigators in human genetics and genetic epidemiologic research, leadership at NIH and CDC, as well as the senior leaders of the for-profit "direct-to-consumer" (DTC) genomic profiling companies (Khoury et al. [@CR42]). At one point in the public session of that meeting, I had the opportunity to ask the panel of corporate leaders if they intended genomic profiles ultimately to be reimbursed by third party carriers as part the personalized medical management of individuals. At that time, not that long ago, the unanimous answer of the CEO's was that their personalized genomics "spit kits" were definitely *not* medical tests and "medicalization" was *not* part of their business model. However, in the past year, spurred by a sharply critical House Committee on Energy and Commerce Subcommittee on Oversight and Investigations report on DTC marketing of personalized genomics, as well as open hearings and device notification letters sent by the FDA (Vorhaus [@CR95]), the mission and marketing strategy of several for-profit genomics profiling providers underwent post-transcriptional modification. Working with laboratories that are CLIA approved, some companies began seeking a role as providers of pre-symptomatic or diagnostic medical tests. While other articles in this volume explore the broad issues of DTC marketing of genomic profiling, our focus here is on the scientific foundation of genomic research and personalized medicine. In this discussion, we will assume that personalized genomics plays a vital, but not exclusive role in an evolving model of personalized *medicine*.

The scope of scientific challenges facing the use of personalized genomics in medicine {#Sec3}
======================================================================================

The scientific foundation for personalized genomics draws on a range of disciplines including, among others, basic genetics, population genetics, genetic and clinical epidemiology, behavioral science, and emerging regulatory science. The applications of genetics and genomics in personalized medicine have included elements of risk assessment, diagnosis, prognosis, and treatment (Table [1](#Tab1){ref-type="table"}). The path from concept to clinical use in each of these domains involves basic, translational, and regulatory science (Hamburg and Collins [@CR35]). The fusion of personal genomics and medicine is informed by reference to the model of four phases of scientific research leading from discovery to improved health outcomes. The first phase (T1) includes discovery and replication of findings, the second (T2) evaluates new tests for validity and utility, the third phase (T3) evaluates best approaches for diffusion and dissemination of tests, and the final phase of translation from bench to bedside (T4) involves research addressing population impact, effectiveness, and economic aspects (Khoury et al. [@CR41]). Across these four phases, research studies evaluate personalized genomics using the "ACCE" framework: analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications (Haddow and Palomaki [@CR34]). This scientific framework encompasses but does not emphasize the notion of "personal utility" of medical tests, which, we will shortly argue, is not a unique feature of "spit test" genomics, but has been a part of medical practice for decades.Table 1Examples of genetic and genomic testing in personalized medicine*Pre-symptomatic risk assessment* *BRCA1/2* testing for breast cancer^a^ Lynch syndrome testing for hereditary colon cancer^b^ Long QT interval^c,d^ Spinal Muscular Atrophy^e^*Diagnosis* Beta thalassemia^f^ Fusion genes and rearrangements including *BCR*-*ABL, E2A*-*PBX1, TEL*-*AML1*, and *MLL* in pediatric leukemia^g^ Gene expression profiles define subtypes of breast cancer^h^ Human Papilloma Virus detection^i^ Hepatitis C detection^j^ PCR detection of micro-organisms (bacteria, fungi)^k^*Prognosis* Fragile X syndrome (number of trinucleotide repeats predicts severity)^l^ Gene expression signatures and prognosis in breast cancer^m^ Gene expression analysis and lymphoma prognosis^n^*Treatment and pharmacogenomics* Therapies for targeted gene mutations in cancer^o^  *EGFR* point mutations in lung cancer and glioblastoma and cetuximab, gefitinib, erlotinib, panitumumab, lapatinib treatment  *KIT*, *PDGFR* mutations in sarcoma, glioma, liver and renal cancer, melanoma and imatinib, nilotinib, sunitinib, sorafenib treatment  *BRAF* mutations in melanoma treated by RAF inhibitors  *BCR*-*ABL* translocation in chronic myelogenous leukemia treated by imatinib  *KRAS* wild-type status correlated with resistance to EGFR inhibition  PARP inhibitors in *BRCA* mutant breast, ovarian, prostate and pancreatic cancer  Herceptin (Trastuzumab) in HER2 + breast cancer Pharmacogenomic applications^p^  *CYP 2C19\*2* variant (rs4244285) associated with diminished clopidogrel response^q^  Rs2395029 testing for HLA-B\*5701 allele, correlated with hypersensitivity to abacavir treatment for HIV+ patients^ra^Robson and Offit ([@CR77]), ^b^ EGAPP ([@CR22]), ^c ^Napolitano et al. ([@CR58]), ^d ^Lehnart et al. ([@CR47]), ^e^ Prior et al. ([@CR74]), ^f^ Galanello and Origa ([@CR28]), ^g ^Carroll et al. ([@CR14]), ^h^ Sorlie et al. ([@CR85]), ^i^ Nicol et al. ([@CR62]), ^j ^Pham et al. ([@CR71]), ^k^ Tsalik et al. ([@CR92]), ^l^ Sherman et al. ([@CR82]), ^m ^Kim and Paik ([@CR43]), ^n ^Rosenwald et al. ([@CR78]), ^o ^Macconaill and Garraway ([@CR49]), ^p ^U.S. Food and Drug Administration ([@CR93]), ^q ^Shuldiner et al. ([@CR84]), ^r ^Colombo et al. ([@CR17])

The lessons of "personalized genetics" relevant to "personalized genomics" {#Sec4}
==========================================================================

The venerable field of genetics refers to the study of single genes, while the emerging field of genomics refers to the study of *all* of a person's genes (Guttmacher and Collins [@CR33]; National Human Genome Research Institute [@CR60]). Distinguished laboratory scientists increasingly speak about the new promise of knowledge of one's "personal genome," predicting a time when genomics will provide warnings and inform preventive actions. Scholars debate whether we are still waiting for the genomics revolution, and if its role in personalized medicine has been overblown (Marshall [@CR54]). Of course, the reality is that many clinicians have been using genetics to personalize practice for decades. As will be argued here, the distinctions between genetics and genomic medicine are more quantitative than qualitative. The traditional dogma is that genetic and genomic medicine are qualitatively different for a variety of reasons including the non-directive nature of genetic counseling for single gene disorders, the use of genetic information for diagnosis in contrast to the use of genomic information (including somatic changes in cancers) as complex biomarkers of risk and outcome, and the interplay of genomics and environmental and epigenetic variables (Guttmacher and Collins [@CR33]; Khoury [@CR40]). As will be argued here, virtually all of these "unique" features of genomics in medicine were presaged and have been incorporated into the translation of genetics to medicine. Over the past decade, the clinical translation of genetics went beyond the largely pediatric and reproductive emphasis of medical genetics, and became part of the core practice of a many fields of medicine, most notably cancer prevention and management (Offit [@CR63]). While the computational challenges of genomics are especially daunting, the translation of genomics to the clinic derives squarely from genetics practice. Indeed, single or multiplexed genetic profiles, have been applied to pre-symptomatic risk assessment, as well as to diagnostic, prognostic, and therapeutic application in several fields, including cancer care. Genetic profiling in personalized medicine is now *de rigueur* in many medical disciplines where it has shifted traditional paradigms (Green and Guyer [@CR31]). In oncology, the use of pre-symptomatic genetic testing and "targeted therapies" tailored to genetic profiles of tumors is part of recommended evaluation for cancers of the colon, lung, breast and other sites (American Society of Clinical Oncology [@CR4], [@CR3], [@CR5]; Robson and Offit [@CR77]; Macconaill and Garraway [@CR49]; McDermott et al. [@CR55]). It is therefore instructive to review some of the insights gleaned from the recent period of scientific discovery and translation to practice of genetic medicine, since the lessons learned are directly relevant to the challenges facing personalized genomics.

*Clinical translation of genetic markers can take place even in the absence of a complete understanding of their functional biologic significance*

The use of linkage or "reverse genetics" led to discoveries of the basis of single gene disorders, such as hemophilia, cystic fibrosis, and breast cancer (reviewed in Botstein and Risch [@CR10]). In the case of *BRCA1*, over 15 years after its discovery, its myriad cellular roles continue to be defined (Boulton [@CR11]), complicating prediction of the functional (hence clinical) significance of missense variants routinely detected (Spearman et al. [@CR86]). The same limitation applies for the estimated 50,000--200,000 single nucleotide polymorphisms (SNPs), which may contribute to disease (Orr and Chanock [@CR69]). Non-synonymous SNPs in exons are the most amenable to estimation of their functional significance, however, even synonymous SNPs can effect mRNA stability and alter splicing signals, and have been linked to diseases such as androgen-insensitivity syndrome and thrombasthenia (Chamary et al. [@CR15]). SNPs in introns and regulatory regions, and SNPs in "gene deserts" may affect gene regulation, as in the case of prothrombin disorders, schizophrenia, or colon cancer (Poort et al. [@CR73]; Law et al. [@CR46]; Pomerantz et al. [@CR72]). Recognizing that most SNPs are merely "markers" of a genetic lesion, and that frequencies of disease-associated SNPs may be obscured or falsely elevated as a result of population heterogeneity, the lack of a precise biological understanding of genetic or genomic associations limits but does not preclude their clinical application. In the mid 1990s, we and others counseled families regarding prophylactic mastectomies based only on markers linked to the *BRCA1* locus. Today, we and others will soon offer testing for risk modifying variants affecting *BRCA2* penetrance and expressivity (Gaudet et al. [@CR30]; Antoniou et al. [@CR6]), even in the absence of knowledge of their function. The proof of clinical utility of genetic or genomic predictive markers does not depend on a complete biological functional understanding of the genetic variant in question, although such an understanding remains critical for pharmacologic targeting.

*Human disease susceptibility is the result of rare genetic variants of high penetrance as well as common genomic variants of low penetrance*

After more than a decade of debate between the Common Disease, Common Variant (CDCV) and Common Disease Rare Variant (CDRV) camps, it is now evident that both sides have won. This debate is reminiscent of a similar dispute, a century earlier, between the "Mendelians" and the "Biometricians," ultimately settled by RA Fisher who established that multiple genes in additive fashion---and following Mendel's laws---could account for continuous variation of phenotypic expression (Provine [@CR75]). With the completion of dozens of genome wide association studies, it is now clear that the bulk of excess familial risk of many diseases is not accounted for by common variants, the so called "missing heritability" of human disease (Maher [@CR50]). This is not to diminish the biological insights made by the GWAS studies, which have elucidated hidden pathways of important etiologic significance. For example, GWAS studies identified the complement pathway in age-related macular degeneration and autophagy pathways in Crohn's disease, as well as a number of pathways not evident from the somatic genetics of cancer (Carvajal-Carmona [@CR150]; Stadler et al. [@CR88]). Most in the field have come to appreciate that both the common and rare variant hypotheses have contributed significantly to our understanding of human disease susceptibility (Schork et al. [@CR80]). Nonetheless, the search continues for the missing heritability of disease, focusing on gene--environment interactions, germline copy number variants, epigenetic and epistatic events, and, most recently, rare variants missed by prior GWAS and linkage approaches but resolvable using next generation sequencing technologies (NGS). The current interest in NGS approaches to discover rare variants, successful thus far in uncovering rare variants associated with recessive syndromes, has proven more challenging for autosomal dominant syndromes, for example, adult-onset cancer families wild-type for known predisposition genes. The lesson being learned in this process, consistent with the overall theme of "new genomics, old lessons," is that unraveling the personalized genome through NGS often relies on traditional genetic approaches. The tens of thousands of coding variants discovered by the average exome scan may be reduced by an order of magnitude by co-segregation of the variant in an affected kindred. The proof of association of these genomic variants will rely on causal evidence of functional significance of the genetic mutations observed. Similarly, the proof of "actionability" of genomic variants at the clinical level will largely rely on empiric approaches established in the era of single gene discovery, validation, and clinical translation.

*Genetic and genomic variants may manifest phenotypically in non-Mendelian patterns*

Another lesson learned from the "personalized genetics" era that should inform the translation of genomics to practice stems from observations of non-Mendelian patterns of inheritance of susceptibility to complex human traits. Such phenomena as imprinting, de novo germline mutations, and epigenetic mechanisms of inheritance are still being defined as they apply to the transmission genetics of single gene disorders. While the de novo mutation rates for some traits such as neurofibromatosis and hereditary endocrine tumors are 30--50% (Garber and Offit [@CR29]), the de novo mutation rates for the most frequent susceptibilities to cancers of the breast and colon remain unclear. De novo germline copy number variation as a mechanism of susceptibility to autism, reviewed in this issue, was a hallmark early discovery of the genomics era (Sebat et al. [@CR81]), and de novo point mutations have recently been observed in individuals affected by mental retardation (Vissers et al. [@CR94]). Studies of de novo genomic variation have not yet been performed for many complex human traits. Non-Mendelian patterns of transmission of epigenetic silencing of genes associated with colon cancer (e.g. *MLH1*), can create a conundrum for genetic counseling due to the observation that epimutation of the promoter of this gene may vary from one generation to the next (Hitchins [@CR37]). Mechanisms of epigenetic silencing of shared promoters of adjacent genes (e.g. *MSH2*, *PTEN/KILLIN*) are still being described (Hitchins [@CR37]; Bennett et al. [@CR8]). Phenomena such as promoter methylation in the germline, not detected on first generation genome scans, will need to be taken into consideration as personalized genomic profiles evolve.

*The genomic model of human disease, like the multifactorial genetic model, will incorporate environmental as well as genetic modifiers*

The genetics era produced important insights into the interaction of genetic and environmental factors, for example the metabolism of carcinogens mediated by xenobiotic genes (Shields and Harris [@CR83]), as well as the first models of pharmacogenetic variants of drug metabolism (Katz and Bhathena [@CR38]). A challenge in the transition from genetics to genomics is the complexity of information; genomic variants may play etiologic roles for a spectrum of diseases, and interact with other variants and environmental factors (Conti et al. [@CR18]). Computational models will need to be developed to determine how polygenes and environmental factors interact to perturb cellular regulatory networks, affecting cellular phenotypes and determining a rationale for targeted prevention of disease (Schadt et al. [@CR79]).

*Analytic validity of genotyping cannot be taken for granted*

Hard lessons were learned during the "personalized genetics" era about the critical translation of genotyping from the research laboratory to the clinic (T2 phase of "laboratory science") (Khoury et al. [@CR42]). Catastrophic results may follow an analytic failure of a single genotype. In one such case, a miscall of a *BRCA* mutation led to an unnecessary surgery and legal action by the patient against the testing laboratory (Peres [@CR70]). At our institution, where the internal clinical lab repeated all positive (and true negative) genotyping results before risk reducing surgeries were recommended, both analytic and post-analytic errors by external academic and commercial laboratories were noted in the years following the initial description of the *BRCA* genes. In the genomics era, similar reporting inconsistencies have also been observed. Several individuals were sent widely divergent results when the same sample was tested in different commercial laboratories, indicating suspected analytic or post-analytic error (Fleming [@CR27]; Davies [@CR19]; Ng et al. [@CR61]).

Encouraged by calls from professional societies (e.g. ASCO [@CR5]), and as required by law in some states such as New York, the same quality assurance standards required for clinical genetic tests are being requested of genomic "profiles" (Vorhaus [@CR95]; Hamburg and Collins [@CR35]). It is now evident that the "T2" phase of clinical laboratory science will not be overlooked in the incorporation of genomics to personalized medicine.

*Behavioral science is needed to inform the translation of genetics (and genomics) to preventive practice, in order to maximize benefit and to avoid the consequences of incomplete risk communication*

One of the most important lessons of the "personalized genetics" era, emerging largely from NHGRI supported research, is that even an analytically and clinically validated genetic test may fail as a tool for prevention or screening unless it is translated to a *behavioral* action by the at-risk individual. A large part of the art as well as practice of genetic counseling is built on a foundation of behavioral research. A goal of applied research in this area has been to minimize the adverse impact of testing, and promote the uptake of recommended primary or secondary preventive interventions following testing (Heshka et al. [@CR36]). Initial reports of self-administered genomic "profiling" confirm that compliance with such interventions as a lower fat diet and exercise were positively impacted by sharing results with a physicians (Bloss et al. [@CR9]). Researchers and practitioners during the era of personalized genetics also discovered that the diffusion of genetic information in families may be highly variable. Families may be dysfunctional; not every individual wants to know genetic information, or wants their relatives to know. Such conflicts can enmesh the genetics practitioner or researcher in the liability trap of the so-called "duty to warn" at-risk relatives (Offit et al. [@CR66]).

*The individual response to probabilistic genetic information varies and depends on context*

There is variation both within families and between individuals regarding the processing of probabilistic risk information, and ability to act on it. For example, Craig Venter pointed out: "...We have, in truth, learned nothing from the genome other than probabilities. How does a 1 or 3 percent increased risk for something translate into the clinic? It is useless information" (Spiegel [@CR87]). From the experience of genetic counseling, we have learned that perceived utility of probabilistic information can depend on the context of presentation. For example, does the 3% increase in risk referred to above pertain to absolute or relative risk? A 3% increase in *absolute* risk of pancreatic cancer, observed in *BRCA2* mutation carriers, from 1 to 4%, is quite significant, while a 3% increase in *relative* risk for pancreatic cancer due to a common SNP (relative risk 1.03 compared to 1.0) indeed seems negligible. For cancer at least, not all SNPs have negligible relative risks (Stadler et al. [@CR88]). For example for both testicular cancer and myeloproliferative disease the increased risks are on the order of two to threefold (Stadler et al. [@CR88]). In addition, while risks are generally quoted for the common heterozygote, the risks for the rare homozygote may be higher; in addition epidemiologic concepts of attributable risk are often misleadingly applied in genomics (Offit [@CR65]). Finally, research has shown that psychosocial context is important for translation of genetic (and genomic) risk information (Heshka et al. [@CR36]).

*Genetic or genomic markers with proven analytic and clinical validity and a strong biological rationale may not meet evidence-based standards of clinical utility*

Over the past two decades clinical investigators have established an evidence base for the utility of genetic tests in a variety of medical contexts. The same will apply to genomic tests. In the area of breast and colon cancer genetics, for example, the clinical utility of genetic testing has been documented (Evaluation of Genomic Applications in Practice and Prevention [@CR22], [@CR23]; Domchek et al. [@CR20]). Numerous professional organizations have conducted evidence reviews, and at the federal level, the need to produce evidence-based recommendations on validity and utility of genomic applications in medicine was recognized by the creation of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group (Teutsch et al. [@CR90]). The EGAPP working group adapted the methods of the US Preventive Services Task Force (USPSTF). It is important to note that these and other groups' evidence-based evaluations did not all reach anticipated conclusions. Of the ten comprehensive reviews carried out or in preparation by EGAPP, all but one have been unfavorable or neutral (Marshall [@CR54]); several of these reports have yet to be published. For example, there was mixed evidence regarding the association between *CYP450* genotypes and selective serotonin uptake inhibitor (SSRI) metabolism, efficacy, and tolerability in the treatment of depression (Evans and Khoury [@CR26]; Agency for Healthcare Research and Quality [@CR2]), and insufficient evidence of clinical utility of *UGT1A1* genotyping to predict toxicity of irinotecan therapy (Evaluation of Genomic Applications in Practice and Prevention [@CR23]). In evaluating the clinical utility of Factor V Leiden (*FVL*) testing alone, or in combination with prothrombin G20210A analysis, there was no direct evidence found to support testing for these mutations leading to improved clinical outcomes in adults with a history of venous thromboembolism or their adult family members (Evaluation of Genomic Applications in Practice and Prevention [@CR25]). Similarly, pharmacogenomic testing to guide warfarin therapy, added to the product label in 2007 by the FDA, was not approved for Medicare reimbursement in mid-2010; large trials to establish the evidence for this example of pharmacogenetics are still in progress (Klein et al. [@CR44]; Conti et al. [@CR18]; Meckley et al. [@CR56]). Despite considerable enthusiasm and a very strong biologic rationale, recent results from two large randomized trials surprisingly failed to support the clinical utility of *CYP2D6* testing accompanying tamoxifen treatment of women with breast cancer (Rae et al. [@CR76]; Leyland-Jones et al. [@CR48]). These findings underscore the critical importance of an evidence base to inform the incorporation of genomics into the practice of medicine, and the potential dangers of self administration of these tests without expert interpretation. The application of traditional evidentiary standards to genomics also may stir debate. For example, it appears that funding for the EGAPP program itself will be seriously diminished in the near future (Marshall [@CR54]). Such developments are particularly difficult at a time when the scientific context for the evaluation of the clinical utility of personalized genomics is comparative effectiveness research, wherein the additive role of genomics is measured compared to existing medical practices (Wilensky [@CR101]).

*The promise of personalized, genomic medicine should be informed by the past decade of experience developing genetically targeted therapies*

In the era of genetically targeted agents, the cost for development of "biological" therapies is fast approaching the \$1.2 billion cost per drug for conventional pharmaceutical development (Malik and Khan [@CR51]). At the same time, large pharmaceutical companies have come to view genetically targeted therapy as a two-edged economic sword. While genomic targeting may identify the proportion of non-responding patients who cause up to 50% of new drugs to fail phase III trials, it will also narrow the target population, decreasing the potential for "blockbuster" drugs. For example, when *KRAS* genotyping of colon tumors was shown to correlate with resistance to pharmacologic inhibition of EGFR, the indicated uses for those drugs diminished. An emerging concern in the genomics era is that some targeted drugs for "orphan diseases" (e.g. PARP inhibitors for *BRCA* mutant tumors) may not meet profitability thresholds set by pharmaceutical companies, or may be marketed for more broadly defined phenotypes where efficacy is more uncertain. While it is true that personalized genomics may improve treatment efficacy and decrease toxicity, a lesson of the genetics era is that the economic hurdles of the biological drug development pipeline remain significant (Malik and Khan [@CR51]).

*Concepts such as "personal utility" and non-traditional modes of delivery of risk information are not new to personalized genomics*

Both genetic and genomic tests may be provided within or outside the realm of health care providers, and both may be deemed to be of value to the individual even if there is no available medical intervention. Distinctions need to be made between DTC marketing of genetic tests with referral to health care professionals, and DTC provision of these services circumventing the health care system (American Society of Clinical Oncology [@CR5]). There is emerging experience with provision of genetic counseling augmented by telemedicine and virtual interactions with health care professionals (Zilliacus et al. [@CR102]). The explicit bypassing of health professionals in the provision of genetic and genomic information of uncertain validity and utility raises risks of false reassurance or false alarm, and consequent adverse psychological sequelae (Offit [@CR64]). Several decades of genetic counseling have resulted in the conclusions by meta-analyses of remarkably few adverse psychological sequelae (Braithwaite et al. [@CR12]; Heshka et al. [@CR36]) following counselor-informed genetic testing. A recent study of 2,037 individuals who self-administered DTC genomic risk profiling with no formal role of genetics professionals found a correlation in test-related distress with lifetime risk (Bloss et al. [@CR9]). Of note, 57 individuals in this series (2.7%) experienced severe (clinically significant) test-related distress by psychometric scales. In the era of genomics, as in genetics, even one strongly adverse reaction resulting in harm to the individual can have profound psychological or even legal consequences.

An implied precept of clinical genetics has been the notion that "personal utility" of a genetic test hinges on an assumption of clinical validity and utility. Implicit in modern medical practice is the principle that personal utility may be derived from knowledge of the risk or diagnosis of untreatable disorders, such as Huntington disease (Wiggins et al. [@CR100]) or Li Fraumeni syndrome (Lammens et al. [@CR45]). Recent findings regarding testing for Alzheimer disease confirm those prior findings; genetic testing of such individuals can be performed without immediate adverse sequelae (Green et al. [@CR32]). However, tests of unknown clinical validity or clinical utility would logically be unsuited to result in "personal utility," unless the perceived utility was based on a misunderstanding of the meaning of the test. In an instructive case, the first individual to have his genome sequence publically disseminated, admitted that he initially misinterpreted the clinical and personal utility of a non-synonymous variant of unknown significance in his *BRCA1* gene, until he consulted a specialist (Watson [@CR97]). Studies of "personal utility" of validated genetic tests were performed at the outset of the genetics revolution; this research concluded that an indeterminate test result for a lethal disease can have the most severe sequelae (Wiggins et al. [@CR100]). This is a lesson especially relevant in the "genomic" era, since, at the present time most, if not all of the common variants for common diseases are, for the most part, not clinically actionable (Evaluation of Genomic Applications in Practice and Prevention [@CR24]; Wellcome Trust Case Control Consortium [@CR99]; Stadler et al. [@CR88]; Manolio [@CR52]). Epistatic interactions between these variants as well as interactions with environmental factors are not yet known, further limiting the immediate prospects for personal utility of self-administered genomic profiles.

*As was the case for genetic counseling for complex disorders, new models for "genomic counseling" are most responsibly offered first in a research and then a clinical context*

The description of the efforts to deduce potentially pathogenic mutations from the genome of a single 40-year-old male (Ashley et al. [@CR7]) supports the rationale for imbedding these efforts in a research context. The reasons for caution revealed in that study include: limitations of current sequencing platforms (e.g. failure to detect structural genomic changes or to distinguish mutations on the same or different chromosomes), the absence of a central repository of rare and disease-causing variants, and the need for longitudinal follow-up to update counseling based on new information (Ormond et al. [@CR68]). The clinical translation of the estimated 50--100 variants implicated in inherited disorders, and present in a "personal genome" (The Thousand Genomes Consortium [@CR91]) will require improved human reference sequence quality, variation, and annotation, which at present require extensive manual analysis and orthogonal validation of variants to derive clinical meaning from the data (Mardis [@CR53]). Current clinical models and training do not readily allow for the timely communication of such a volume of genetic information to individuals (Ormond et al. [@CR68]). While unraveling of the genomes of a dozen cancer types has led to the discovery of several new oncogenes and tumor suppressor genes (e.g. *IDH1* mutations in leukemia and glioblastoma, *DPP10* deletions in mesothelioma, novel translocations in prostate cancer), the translation of these findings to personalized therapeutics also remains a research-in-progress (Weinberg [@CR98]). The interpretation, counseling, and medical implications resulting from analysis of individual germline or cancer-derived genome sequences will likely entail higher human costs and liabilities than costs to generate the genotypes (Mardis [@CR53]).

As these data on rare germline and somatic variants continues to accumulate, the path for clinical validation will be built using a multidisciplinary approach to genomic counseling. The spectrum of evidentiary standards required for personalized medicine is illustrated by two panels tasked to review personalized genomic data in different research and clinical contexts. For the EGAPP Working Group, the criteria for clinical utility of testing were the "high bar" established by evidence-based reviews. The reviews of a single or panels of genetic variants took a year or more to complete, and often failed to document evidence of clinical utility (Evaluation of Genomic Applications in Practice and Prevention [@CR22], [@CR23], [@CR24], [@CR25]; Evans and Khoury [@CR26]). However, for a study using a panel of SNPs to assess the impact of personalized genomics on 4,372 individuals, the scientific advisory board was tasked with evaluating clinical validity of the SNP and if the SNP was *potentially actionable* (Keller et al. [@CR39])*.* In just a few meetings, 17 SNPs were approved (2 not approved) for inclusion. Because genomic profiling was being offered in the context of a longitudinal research study, the ethical and scientific conduct of the study allowed for communication of genomic markers of unproven clinical utility. Such an investigational path for the translation of personalized genomics resembles that proposed in the early days of *BRCA* analysis, when testing was encouraged in the context of longitudinal research studies (American Society of Clinical Oncology [@CR4]). It is also consistent with current emerging consensus in the bioethical community that the issue is no longer if genomic information should be returned to consenting individuals in the context of research, but how to do this while avoiding harm (Bredenoord et al. [@CR13]).

*The same range of ethical issues apply to "personalized genomics" as to personalized genetics*

The era of personalized genetics brought with it a focus on ethical implications of research and the process of informed consent. For example, the informed consent for genetic testing for cancer includes 14 elements (American Society of Clinical Oncology [@CR5]). These same elements, relating to potential risks and benefits, are relevant to genomic testing and research. In addition, a move toward transparency of disclosure now requires scientists, physicians, and genetic counselors who are either directly employed or derive benefit from for-profit genomic testing companies to reveal those conflicts of interest. Consumers are now being marketed to seek guidance from professionals who have other than a fiduciary responsibility to them as patients. Disclosure of personal conflicts of interest is a key element in the provision of personalized medicine. Another emerging ethical issue bearing on the translation of genetics and genomics to personalized medicine is equity and access; there is the risk that these technologies will be available only to the affluent (Mardis [@CR53]). This, in fact, was the experience in the clinical dissemination of preimplantation genetic diagnosis (Offit et al. [@CR67]). Finally, as mentioned, there remains inconsistency in the ethical and legal definitions of "duty to warn" family members at potentially increased genetic---or genomic risk---of a disease or adverse outcome (Offit et al. [@CR66]). In an era of over a half dozen "black box" FDA warnings, and over 60 labels with information regarding dosing or toxicity guidance based on genetic markers, it is known that risks for toxicity or altered metabolism follow Mendelian patterns. The unit of concern in genomics, as in genetics, is the risk to the family and not simply the individual.

Concluding comments {#Sec17}
===================

There is little debate that the extraordinary progress in genome science over the past decade, coupled with the declining cost of sequencing technologies, has brought the promise of personalized medicine closer than ever. However it still remains true, as Harold Varmus once said, that genomics is more a way to do science, not medicine (Wade [@CR96]). Many in the field also share David Altshuler's skepticism about the promise of personalized medicine when it comes to common, complex diseases (Dougherty [@CR21]). While it is true that the Human Genome Project has not yet directly affected the health care of most individuals, there have been dramatic examples of genetically targeted treatment and prevention, notably in the field of oncology (Collins [@CR16]; Macconaill and Garraway [@CR49]; Green and Guyer [@CR31]). The past decade of translation of genetics to personalized medicine provides a roadmap to inform the incorporation of genomics into clinical practice during the decade ahead. For common variants, the paradox remains that that personalized medicine now requires population-sized experiments to explore common polygenes, environmental factors, and clinical endpoints (Orr and Chanock [@CR69]). For rare disease predisposition syndromes and individual cancer genomes, the progress of sequencing technologies has made personalized genomics a reality (Meyerson et al. [@CR57]). The computational and counseling challenges resulting from the emerging deluge of next generation sequencing data constitutes a barrier that will need to be surmounted to translate genomics research to practice, and to emerge from what Elaine Mardis has called the era of the \$1,000 genome and the \$100,000 analysis (Mardis [@CR53]). Throughout this process, more clinical research in the validation (T2) and cost effectiveness (T4) end of the spectrum will be required to produce the evidentiary database to inform the practice of personalized medicine (Khoury et al. [@CR41]). Commercial genomic testing labs, as well as genomics-based pharmaceutical companies will require this evidentiary foundation to obtain reimbursement for medical services. During this period of transition from investigation to practice, efforts will be needed to protect consumers against potential harms of premature translation of research findings, while encouraging innovative and cost effective application of those genomic discoveries that improve personalized medical care.

K. Offit is a member of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, an independent advisory group to the US Center for Disease Control, and currently chairs a working group considering issues of intellectual property in cancer genetics for the American Society of Clinical Oncology (ASCO). The views expressed in this article do not represent those of EGAPP, the CDC, ASCO, or the Memorial Sloan-Kettering Cancer Center. Dr Offit has no investments in and does not sit on any paid advisory boards for commercial entities involved in personalized genomics. K. Offit is indebted to William Foulkes, M.B., Ph.D., and Mark E. Robson, M.D. for thoughtful discussions, and to Peter Thom, M.S., C.G.C., who assisted in the preparation of the Table and bibliographic research. This project was supported in part by the Robert and Kate Niehaus Clinical Cancer Genetics Initiative and The Sharon Levine Corzine Genetic Research Fund.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
